Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301

NCT04541043 is registered in ClinicalTrials.gov with Calliditas Therapeutics AB as lead sponsor.

NCT NCT04541043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301
Lead sponsor
Calliditas Therapeutics AB
Phase
Phase 3
Overall status
Completed
Start date
November 17, 2020
Completion date
February 26, 2024
Enrollment
119 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

primary iga nephropathy